
Stephen Liu/LinkedIn
Jul 21, 2025, 14:04
Stephen V Liu: Positive Update from FLAURA2 Trial on EGFR NSCLC Treatment
Stephen V Liu, Chief, Division of Hematology and Oncology at Georgetown Lombardi Comprehensive Cancer Center, Director of Thoracic Oncology and Developmental Therapeutics, shared a post on X:
“FLAURA2 press release: addition of chemotherapy to 1L osimertinib in EGFR NSCLC improves overall survival. Already approved based on significant PFS benefit. Awaiting data to see degree of OS benefit to consider vs MARIPOSA. Important positive update!”
Read Full Press Release.
Read More about NSCLC on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 21, 2025, 14:04
Jul 21, 2025, 13:14
Jul 21, 2025, 13:00
Jul 21, 2025, 12:50
Jul 21, 2025, 12:47
Jul 21, 2025, 12:30
Jul 21, 2025, 12:30